Notably, CD96 signaling dysregulation in T cells has been linked to impaired anti-tumor immunity and poor clinical outcomes, implying that targeting this pathway could enhance the therapeutic effect for this patient, providing a personalized treatment direction [35,36]. Here, CD96 is linked to neoplasm.